Prof. Dr. Ferdinandy Péter

„He is listed in the Highly Cited Researcher 2014, 2017, 2020-2024 databases acknowledging the world’s most influential scientists (see link). He published more than 380 papers in international peer-reviewed journals with an impact factor over 1 400 and over 26 000 citations. He is the Editor-in-Chief of the British Journal of Pharmacology as well as member of the editorial boards of Basic Res Cardiol, J Mol Cell Cardiol, and J Pharmacol Toxicol Methods. Péter was the president of the International Society for Heart Research, European Section, and the chair of the Working Group of Cellular Biology of the Heart of the ESC. Currently he is the president of the Hungarian Society of Experimental and Clinical Pharmacology (www.huphar.org) and Executive Committee member of the European Federation of Pharmacological Societies. Péter received an MD diploma in 1991 and a PhD degree in 1995 from the University of Szeged. He became a registered clinical pharmacologist in 1999, and obtained his DSc degree of the Hungarian Academy of Sciences in 2004. He completed MBA studies in Finance and Quality Management in 2004 at the Budapest University of Technology and Economics. He worked for 2 years at the Department of Pharmacology, University of Alberta, Edmonton, Canada, as a postdoctoral fellow of MRC Canada. He was the head of the Cardiovascular Projects at Biorex Co (a partner of Abbott), a US-Hungarian biotech company, and consulted preclinical and clinical pharmacological projects for several pharmaceutical companies all over the world in the last 20 years. He was the founder of the Cardiovascular Research Group at the University of Szeged, see www.cardiovasc.com. He is a professor of pharmacology and clinical pharmacology, head of the Department of Pharmacology and Pharmacotherapy, Semmelweis University, and became vice-rector for science and innovations of the Semmelweis University in 2018.”